These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

371 related articles for article (PubMed ID: 19415280)

  • 41. [Incidence of infusion reactions induced by cetuximab chemotherapy].
    Maeda T; Tatematsu M; Muro K
    Gan To Kagaku Ryoho; 2011 Jun; 38(6):963-6. PubMed ID: 21677487
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anti-epidermal growth factor receptor monotherapy in the treatment of metastatic colorectal cancer: where are we today?
    Peeters M; Price T; Van Laethem JL
    Oncologist; 2009 Jan; 14(1):29-39. PubMed ID: 19144681
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Panitumumab (Vectibix) for metastatic colorectal cancer.
    Med Lett Drugs Ther; 2007 Apr; 49(1259):35-6. PubMed ID: 17450113
    [No Abstract]   [Full Text] [Related]  

  • 44. Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.
    Burtness B
    Oncology (Williston Park); 2007 Jul; 21(8):964-70; discussion 970, 974, 976-7. PubMed ID: 17715697
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cutaneous toxicity from epidermal growth factor receptor inhibitors: would a subcutaneous desensitization be helpful? Case report.
    D'Alessio A; Cecchini S; Di Mauro D; Geroli L; Villa S; Quadri A; Resta D; Fortugno C
    Tumori; 2016 Nov; 102(Suppl. 2):. PubMed ID: 27791234
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Epidermal growth factor receptor expression discrepancies in metastatic colorectal cancer patients treated with cetuximab plus irinotecan-based chemotherapy refractory to irinotecan and oxaliplatin.
    Han HS; Chang HJ; Hong YS; Kim SY; Lee KS; Jung KH
    Dis Colon Rectum; 2009 Jun; 52(6):1144-51; discussion 1152-3. PubMed ID: 19581859
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Relationship between the Incidence of Hypomagnesemia and Acneiform Rash and the Therapeutic Effect of Anti-EGFR Monoclonal Antibody in Patients with Metastatic Colorectal Cancer].
    Fujii H; Iihara H; Ishihara M; Matsuhashi N; Takahashi T; Yoshida K; Itoh Y
    Gan To Kagaku Ryoho; 2016 Feb; 43(2):229-33. PubMed ID: 27067688
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
    Eder J; Simonitsch-Klupp I; Trautinger F
    Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.
    Cunningham D; Humblet Y; Siena S; Khayat D; Bleiberg H; Santoro A; Bets D; Mueser M; Harstrick A; Verslype C; Chau I; Van Cutsem E
    N Engl J Med; 2004 Jul; 351(4):337-45. PubMed ID: 15269313
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Six cases of treatment with panitumumab in patients with severe hypersensitivity reactions to cetuximab.
    Nielsen DL; Pfeiffer P; Jensen BV
    Ann Oncol; 2009 Apr; 20(4):798. PubMed ID: 19254943
    [No Abstract]   [Full Text] [Related]  

  • 51. FDA drug approval summary: panitumumab (Vectibix).
    Giusti RM; Shastri KA; Cohen MH; Keegan P; Pazdur R
    Oncologist; 2007 May; 12(5):577-83. PubMed ID: 17522246
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemotherapy with targeted agents for the treatment of metastatic colorectal cancer.
    Köhne CH; Lenz HJ
    Oncologist; 2009 May; 14(5):478-88. PubMed ID: 19411318
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity of panitumumab in combination chemotherapy clinical trials.
    Weeraratne D; Chen A; Pennucci JJ; Wu CY; Zhang K; Wright J; Pérez-Ruixo JJ; Yang BB; Kaliyaperumal A; Gupta S; Swanson SJ; Chirmule N; Starcevic M
    BMC Clin Pharmacol; 2011 Nov; 11():17. PubMed ID: 22070868
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Cetuximab efficacy and safety in a retrospective cohort of elderly patients with heavily pretreated metastatic colorectal cancer.
    Bouchahda M; Macarulla T; Spano JP; Bachet JB; Lledo G; Andre T; Landi B; Tabernero J; Karaboué A; Domont J; Levi F; Rougier P
    Crit Rev Oncol Hematol; 2008 Sep; 67(3):255-62. PubMed ID: 18400508
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Pre-emptive skin toxicity treatment for anti-EGFR drugs: evaluation of efficacy of skin moisturizers and lymecycline. A phase II study.
    Grande R; Narducci F; Bianchetti S; Mansueto G; Gemma D; Sperduti I; Trombetta G; Angelini F; Gamucci T
    Support Care Cancer; 2013 Jun; 21(6):1691-5. PubMed ID: 23314653
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Desensitization to oxaliplatin with two stages of premedication in a patient with metastatic rectal cancer.
    Nozawa H; Muto Y; Yamada Y
    Clin Ther; 2008 Jun; 30(6):1160-5. PubMed ID: 18640472
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Anti-epidermal growth factor receptor monoclonal antibodies induced adverse events].
    Tsuji Y; Kogawa T; Abe M
    Gan To Kagaku Ryoho; 2010 May; 37(5):787-90. PubMed ID: 20495307
    [TBL] [Abstract][Full Text] [Related]  

  • 59. First-line use of anti-epidermal growth factor receptor monoclonal antibodies in metastatic colorectal cancer.
    Lee JJ; Chu E
    Clin Colorectal Cancer; 2007 Oct; 6 Suppl 2():S42-6. PubMed ID: 18021486
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.
    Van Cutsem E; Peeters M; Siena S; Humblet Y; Hendlisz A; Neyns B; Canon JL; Van Laethem JL; Maurel J; Richardson G; Wolf M; Amado RG
    J Clin Oncol; 2007 May; 25(13):1658-64. PubMed ID: 17470858
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.